Join the club for FREE to access the whole archive and other member benefits.

'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases

Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood

09-Sep-2021

Key points from article :

Underdog Pharmaceuticals has been awarded an Innovation Passport under the UK’s Innovative Licensing and Access Pathway (ILAP).

It is on a mission – not to treat age-related diseases, but to tackle the causes using simple and direct interventions.

By targeting oxidised cholesterol, it aims for the first true disease-modifying treatment for atherosclerosis, heart attack & stroke.

Products are based on novel derivatives of a well-known, safe compound.

Custom-engineered cyclodextrins tackle cholesterol derivatives such as 7-ketocholesterol.

UDP-003 is designed to target and remove toxic oxidised cholesterol, a key driver of arterial plaque accumulation.

Underdog is one of the first companies, and UDP-003 one of the very few pre-clinical therapies, to receive an ILAP designation.

“There is an enormous public need for drugs which can significantly reverse atherosclerosis, rather than manage or delay its onset,” - Matthew O’Connor, Underdog CEO of Scientific Affairs.

Mentioned in this article:

Click on resource name for more details.

Cyclarity Therapeutics

Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases

Matthew O’Connor

Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)

Topics mentioned on this page:
Heart Disease